Immune checkpoint blockade (ICB) demonstrated modest clinical activity in patients with metastatic castration-resistant prostate cancer (CRPC). However, it is unclear if radiation therapy synergizes with ICB to enhance the antitumor immune response.
Immune checkpoint blockade (ICB) demonstrated modest clinical activity in patients with metastatic castration-resistant prostate cancer (CRPC). However, it is unclear if radiation therapy synergizes with ICB to enhance the antitumor immune response.